Avicanna (0NN) Stock Price & Analysis
0NN Stock Chart & Stats
- Day’s Range
- EUR 0.06 - EUR 0.06
- 52-Week Range
- EUR 0.06 - EUR 0.19
- Previous Close
- EUR 0.06
- Volume
- N/A
- Average Volume (3M)
- 333
- Market Cap
- EUR 9.04M
- Enterprise Value
- EUR 25.16M
- Total Cash (Recent Filing)
- EUR 200.42K
- Total Debt (Recent Filing)
- EUR 169.56K
- Price to Earnings (P/E)
- ―
- Beta
- 0.76
- Next Earnings
- Nov 12, 2026 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Gross Margin
Gross margins above 50% in 2024–TTM show that Avicanna’s products retain meaningful economics after direct costs. This provides a stronger foundation for future operating improvement, although the company still needs sufficient scale and cost discipline to convert that margin into profit.
Manageable Leverage
Low debt and modest debt relative to equity reduce immediate balance-sheet pressure and preserve financial flexibility compared with the stress seen in 2022–2023. This gives Avicanna more capacity to manage operations while pursuing improvement, despite continuing losses.
Historical Revenue Expansion
Material revenue expansion from 2021 through 2024 demonstrates that Avicanna has previously increased its commercial scale. That established base can support operating leverage if growth resumes, though the recent flattening means this remains a historical strength rather than current momentum.
Bears Say
Persistent Cash Burn
Negative operating and free cash flow across every reported period means the business has not yet funded itself through operations. Continued cash burn can constrain investment and increase reliance on external financing, making sustained cash break-even a central requirement for stability.
Ongoing Unprofitability
Avicanna’s negative EBIT, EBITDA, and net income show that its roughly 50%+ gross margin is not yet covering operating costs. Persistent losses weaken internal capital generation and indicate that further scale, expense control, or both are needed before earnings become durable.
Stalling Revenue Growth
Flattening revenue followed by slightly negative TTM growth weakens the near-term path to operating leverage. Without renewed demand or commercial expansion, the company may struggle to spread fixed costs across a larger base, delaying progress toward profitability and cash-flow break-even.
Avicanna News
0NN FAQ
What was Avicanna’s price range in the past 12 months?
What is Avicanna’s market cap?
When is Avicanna’s upcoming earnings report date?
How were Avicanna’s earnings last quarter?
Is Avicanna overvalued?
Does Avicanna pay dividends?
What is Avicanna’s EPS estimate?
How many shares outstanding does Avicanna have?
What happened to Avicanna’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Avicanna?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Avicanna
Avicanna Inc., a biopharmaceutical firm headquartered in Toronto, Canada, and founded in 2016, is actively engaged in the research, development, and commercialization of scientifically validated products for both global medical and consumer health markets. The company's comprehensive scientific framework encompasses R&D and clinical trials, often undertaken in collaboration with Canadian academic and medical institutions. This effort has yielded around twenty commercialized products spanning four primary market categories. These offerings include medical and wellness items under the RHO Phyto brand, featuring cannabinoids such as CBD, CBG, and THC; CBD-infused topical and derma-cosmetic products marketed under the Pura H&W and Pura Earth labels; and bulk cannabis and hemp-derived raw materials like dried flowers, standardized seeds, full-spectrum extracts, cannabinoid distillates, and isolates, provided through the Aureus brand. Additionally, Avicanna is advancing a pharmaceutical pipeline focused on treatments for conditions including epidermolysis bullosa, dermatological ailments, chronic pain, and various neurological disorders. A notable research partnership with Dr. Christine Allen's Research Group is dedicated to developing a cannabinoid-based therapy for lung inflammation linked to COVID-19.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Aras Azadian Mba
- Employees
- 112
- Website
- www.avicanna.com
- Address
- 480 University Avenue, Toronto, ON, M5G 1V2, CA
Avicanna (0NN) Earnings & Revenues
0NN Earnings Call
Earnings Call SentimentPositive
The call emphasized material operational and scientific progress—improved gross margins (53%, +10 pts), reduced operating expenses (–9%), stronger liquidity (working capital +23%), R&D/IP milestones (PwdRX/data and new USPTO patent), and clinical advancements (450 patient RWE study published; Phase II underway). These positives were tempered by flat top-line revenue at $25.5M, a still-negative full-year adjusted EBITDA (–$300k) and net loss ($2.7M), early-stage commercial launches (soft launch of Trunerox) and ongoing regulatory and market uncertainties (U.S. rescheduling dependency and stock overhang). On balance, the company presented clear momentum on margins, efficiency, IP and clinical programs while acknowledging remaining commercialization and market-risk headwinds.
View all DE:0NN earnings summariesTechnical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 10 | 4 | 8 |
| Technical Analysis | 4 | 4 | 2 |
| Moving Averages | 6 | 0 | 6 |








